NCT02048787 Pharmacokinetic Study of Buparlisib in Subjects With Renal Impairment. Status COMPLETED Phase PHASE1
NCT02047656 To Evaluate Pharmacokinetics of LFF269 in Healthy Volunteers and Patients With Hypertension Status TERMINATED Phase PHASE1
NCT02044848 Study of Secukinumab in Patients With Newly-diagnosed Type 1 Diabetes Mellitus Status TERMINATED Phase PHASE2
NCT02042014 Open-label, Multi-center Protocol to Provide QTI571 to PAH Patients Who Participated in the Extension Study (A2301E1) in Japan Status COMPLETED Phase PHASE3
NCT02040870 LDK378 in Adult Chinese Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib Status COMPLETED Phase PHASE1/PHASE2
NCT02040584 A Multicentre, Randomised, Open-label, Controlled, 12-month Follow-up Study to Assess Impact on Renal Function of an Immunosuppression Regimen Based on Tacrolimus Minimisation in Association With Everolimus in de Novo Liver Transplant Recipients. Status COMPLETED Phase PHASE3
NCT02039947 Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain Status COMPLETED Phase PHASE2
NCT02038049 A Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity in Patients With Relapsing-remitting Multiple Sclerosis Status TERMINATED Phase PHASE2
NCT02038036 Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy. Status COMPLETED Phase PHASE3
NCT02034110 Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers Status COMPLETED Phase PHASE2
NCT02034006 A Study of the Criteria Establishing the Need for Re-treatment With Ranibizumab Upon Relapse in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia. Status COMPLETED Phase PHASE3
NCT02032173 Efficacy and Safety of Lucentis® Use in Patients With Diabetic Macular Edema Evaluating a Spaced Out Follow-up After Intensive Treatment Phase Status TERMINATED Phase PHASE3
NCT02024932 Safety, Tolerability, and Efficacy of BVS857 in Patients With Spinal and Bulbar Muscular Atrophy Status COMPLETED Phase PHASE2
NCT02023151 Predicting the Clinical Response to Omalizumab With Anti-Immunoglobulin E (IgE) Ab Response or Syk Expression in Basophils Status COMPLETED Phase PHASE4
NCT02017860 Study to Collect and Assess Long-term Safety of Everolimus in Patients Who Are on Everolimus Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator. Status COMPLETED Phase PHASE2
NCT02015663 Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles Status TERMINATED Phase PHASE4
NCT02014636 Safety and Efficacy Study of Pazopanib and MK 3475 in Advanced Renal Cell Carcinoma (RCC; KEYNOTE-018) Status COMPLETED Phase PHASE1
NCT02008916 16-week Efficacy and 3-year Safety, Tolerability and Efficacy of Secukinumab in Active Ankylosing Spondylitis Patients Status COMPLETED Phase PHASE3
NCT02008890 Palmoplantar Pustular Psoriasis Efficacy and Safety With Secukinumab Status COMPLETED Phase PHASE3